GlobeNewsWire
14 Jun 2026, 22:05 UTC · 13w ago
Verdict
Headline takes no side. We score ZYME +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
ZW191 demonstrated a confirmed overall response rate (cORR) of 78.6% in patients with FRα-positive platinum-resistant ovarian cancer.
So whatHigh efficacy in a difficult-to-treat cancer population is a primary driver for biotech valuation and future FDA approval prospects.
More positive than 98% of claims this week
ZW191 showed anti-tumor activity in FRα-negative tumors, with a cORR of 47.4% in ovarian and 40.0% in endometrial cancer patients.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 91% of claims this week
The study reported a median progression-free survival of 7.6 months and that the median duration of response had not yet been reached.
So whatPositive durability data suggests a sustained clinical benefit, which is critical for moving from Phase 1 to pivotal trials.
More positive than 84% of claims this week
Grade ≥3 treatment-emergent adverse events occurred in 55% of patients, with 20% discontinuing treatment due to adverse events.
More negative than 73% of claims this week
Enrollment for Part 2a (dose optimization in ~60 PROC patients) has been completed, with data expected at a future meeting.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company presented positive Phase 1 clinical data demonstrating compelling anti-tumor activity and a manageable safety profile for ZW191.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
+16.5%
Price agrees with the score
$26.66 vs $22.88 close before publication (Jun 12) · not market-adjusted
ZYME chart →
